NASDAQ: FNCHFinch Therapeutics Group Inc Stock
$0.41+0.04 (+10.81%)
Updated Mar 27, 2023
FNCH Price
$0.41
Fair Value Price
$1.86
Market Cap
$19.50M
52 Week Low
$0.30
52 Week High
$5.45
P/E
-0.17x
P/B
0.2x
P/S
26.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$861.00k
Earnings
-$114.65M
Gross Margin
100%
Operating Margin
-13,315.45%
Profit Margin
-13,315.4%
Debt to Equity
0.7
Operating Cash Flow
-$75M
Beta
0.9
Next Earnings
May 11, 2023
Ex-Dividend
N/A
Next Dividend
N/A
FNCH Overview
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered drugs in the U.S. The company collaborates and has license agreements with Takeda Pharmaceutical Company Ltd, Skysong Innovations LLC, and the University of Minnesota. The company was incorporated in 2014 and is based in Somerville, MA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FNCH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FNCH ($0.41) is undervalued by 78.22% relative to our estimate of its Fair Value price of $1.86 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FNCH ($0.41) is significantly undervalued by 78.22% relative to our estimate of its Fair Value price of $1.86 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FNCH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FNCH due diligence checks available for Premium users.
Be the first to know about important FNCH news, forecast changes, insider trades & much more!
FNCH News
Valuation
FNCH fair value
Fair Value of FNCH stock based on Discounted Cash Flow (DCF)
Price
$0.41
Fair Value
$1.86
Undervalued by
77.95%
FNCH ($0.41) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FNCH ($0.41) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FNCH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FNCH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
18.55x
Market
21.44x
FNCH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.2x
Industry
4.86x
FNCH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FNCH's financial health
Profit margin
Revenue
$8.0k
Net Income
-$27.0M
Profit Margin
-337,600%
FNCH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FNCH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$162.9M
Liabilities
$67.2M
Debt to equity
0.7
FNCH's short-term assets ($74.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FNCH's short-term assets ($74.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FNCH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.3M
Investing
-$51.0k
Financing
$52.0k
FNCH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FNCH vs Biotech Stocks
Finch Therapeutics Group Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.